Hospital Variability in the Use of Vasoactive Agents in Patients Hospitalized for Acute Decompensated Heart Failure: Clinical Phenotypes and Therapeutic Approaches
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
ABSTRACT Background The absence of practice standards in vasoactive agent usage for acute decompensated heart failure (ADHF) has resulted in significant treatment variability across hospitals, potentially affecting patient outcomes. This study aimed to assess temporal trends and institutional differences in vasodilator and inotrope/vasopressor utilization among ADHF patients, considering their clinical phenotypes. Methods Data were extracted from a government-funded multicenter registry covering the Tokyo metropolitan area, comprising 44,444 consecutive patients urgently hospitalized in intensive/cardiovascular care units with a primary diagnosis of ADHF between 2013 and 2021. Clinical phenotypes, i.e., pulmonary congestion or tissue hypoperfusion, were defined through a comprehensive assessment of clinical signs and symptoms, vital signs, and laboratory findings. We assessed the frequency and temporal trends in phenotype-based drug utilization of vasoactive agents and investigated institutional characteristics associated with adopting the phenotype-based approach. Results Throughout the study period, both overall and phenotype-based vasodilator utilization showed significant declines, with overall usage dropping from 61.4% in 2013 to 48.6% in 2021 ( p for trend < 0.001). Conversely, no temporal changes were observed in overall inotrope/vasopressor utilization from 24.6% in 2013 to 25.8% in 2021 or the proportion of phenotype-based utilization. Notably, there was considerable variability in phenotype-based drug utilization among hospitals, ranging from 0% to 100%. Particularly, hospitals with a large number of board-certified cardiologists demonstrated reduced phenotype-based vasodilator utilization and phenotypically inappropriate inotrope/vasopressor utilization over time. Conclusions Substantial variability existed among hospitals in phenotype-based drug utilization of vasoactive agents for ADHF patients, highlighting the need for standardization in their adoption during hospitalization. Key Learning Points a. What is known The absence of standardized drug utilization practices for acute decompensated heart failure contributes to notable variations in treatment approaches across different healthcare facilities, and these facility-specific differences have potential to influence patient outcomes. b. What the study adds This study demonstrated that, using a government-funded multicenter registry of hospitalized patients for acute decompensated heart failure, overall and phenotype-based inotrope/vasopressor utilization was relatively stable between 2013 and 2021, while significant declines in both overall and phenotype-based vasodilator utilization was observed over the same period. Significant variability was noted in the extent of phenotype-based drug utilization among hospitals, with the utilization rates ranging from 0% to 100%: Specifically, hospitals with a large number of board-certified cardiologists demonstrated gradual declines in phenotype-based vasodilator utilization and phenotypically inappropriate utilization of inotropes/vasopressors.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Hospital Variability in the Use of Vasoactive Agents in Patients Hospitalized for Acute Decompensated Heart Failure: Clinical Phenotypes and Therapeutic Approaches
- Date Crossref
- 27/05/2024
- Éditeur
- openRxiv
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Keio University Department of Cardiology pays non établi dans la noticeUniversité ou école supérieure
-
Tokyo Health Care University pays non établi dans la noticeUniversité ou école supérieure
-
Tokyo Medical Center pays non établi dans la noticeÉtablissement de santé
-
National Hospital Organization pays non établi dans la noticeOrganisme public
-
Tokyo National Hospital pays non établi dans la noticeÉtablissement de santé
-
Tokyo Metropolitan Geriatric Hospital pays non établi dans la noticeÉtablissement de santé
-
Kyorin University pays non établi dans la noticeUniversité ou école supérieure
-
Saiseikai Central Hospital pays non établi dans la noticeÉtablissement de santé
-
Tokyo City University pays non établi dans la noticeUniversité ou école supérieure
-
The University of Tokyo pays non établi dans la noticeUniversité ou école supérieure
-
Tokyo Medical University pays non établi dans la noticeUniversité ou école supérieure
-
Nippon Medical School pays non établi dans la noticeUniversité ou école supérieure
Department of Cardiology — Keio University, Tokyo Health Care University et Tokyo Medical Center, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.